Virology & Infectious Diseases RFP Opportunities
Gilead Sciences funds research advancing clinical and implementation science in HIV, hepatitis, and antifungal therapies to improve outcomes and access for underserved populations worldwide.
Funder: Gilead Sciences
Due Dates: January 30, 2026 (INCLUSION Global LOI) | April 3, 2026 (INCLUSION Global Full) | May 4, 2026 (RESONATE LOI) | May 29, 2026 (RESONATE Full) | June 30, 2026 (AmBisome LOI) | July 12, 2026 (GATHER AND LISTEN LOI)
Funding Amounts: Up to $5,000,000 (INCLUSION Global 2026) | Up to $4,000,000 (RESONATE 2026) | Funding for GATHER AND LISTEN and AmBisome not specified; typical project budgets vary, overhead capped at 30%.
Summary: Supports research in virology and infectious diseases—especially HIV, hepatitis, and antifungal therapy—to improve outcomes and access for diverse patient populations.
Key Information: Multiple RFPs with distinct topics and eligibility; LOI required before full application.
Description
Gilead Sciences offers a suite of externally sponsored research funding opportunities focused on advancing clinical and implementation science in virology and infectious diseases. The program encompasses several targeted RFPs, each with its own research focus, including innovative HIV prevention strategies, HIV treatment outcomes, integrated care for viral hepatitis, and studies on antifungal therapies (notably AmBisome). The overarching goal is to support research that addresses unmet needs, improves equitable access, and enhances health outcomes in diverse and often underserved populations globally.
